S. Pastidis

Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation

J. Kliment, C. Robertson, P. Whelan, 2008 .

Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.

J. Kliment, T. Oliver, C. Robertson, 2014, European urology.